Can I read Long-term HIV and tuberculosis outcomes in patients hospitalised with severe cutaneous adverse reactions on EtoBox?

Long-term HIV and tuberculosis outcomes in patients hospitalised with severe cutaneous adverse reactions by S. Veenstra; M.N. Porter; B.N. Thwala; N. Pillay; M.A. Panieri; J. van der Westhuizen; E.J. Phillips; G. Meintjes; S. Dlamini; R.J. Lehloenya; J. Peter is a Medicine article available to read on EtoBox.

What is Long-term HIV and tuberculosis outcomes in patients hospitalised with severe cutaneous adverse reactions about?

## Background Treatment-limiting severe cutaneous adverse reactions (SCAR) occur more commonly amongst persons with HIV-associated tuberculosis (TB). The impact of SCAR on long-term HIV/TB outcomes is unknown. ## Methods Patients with TB and/or HIV admitted to Groote Schuur Hospital, Cape Town, South Africa with SCAR between 1/10/2018 and 30/09/2021 were eligible. Follow-up data was collected for 6- and 12-month outcomes: mortality, TB and antiretroviral therapy (ART) regimen changes, TB treatment completion, and CD4 count recovery. ## Results Forty-eight SCAR admissions included: 34, 11, and 3 HIV-associated TB, HIV-only and TB-only patients with 32, 13 and 3 cases of drug reaction with eosinophilia and systemic symptoms, Stevens-Johnson syndrome/toxic epidermal necrolysis and generalised bullous fixed-drug eruption respectively. Nine (19%), all HIV-positive (eight co-infected with TB), were deceased at 12-months, and 12(25%) were lost to follow-up. Amongst TB-SCAR patients, seven (21%) were discharged on all four first-line anti-TB drugs (FLTD), while 12(33%) had regimens with no FLTDs; 24/37(65%) completed TB treatment. Amongst HIV-SCAR patients, 10/31(32%) changed ART regimen.

Who reads Long-term HIV and tuberculosis outcomes in patients hospitalised with severe cutaneous adverse reactions?

Author

S. Veenstra; M.N. Porter; B.N. Thwala; N. Pillay; M.A. Panieri; J. van der Westhuizen; E.J. Phillips; G. Meintjes; S. Dlamini; R.J. Lehloenya; J. Peter

Publisher

Elsevier BV

Published

2023

Language

EN

Field

Medicine (Health Sciences)